Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Treatment of young adults with colorectal cancer (CRC) represents an unmet clinical need,
especially as diagnosis in this population might lead to the greatest loss of years of life …

DNA damage repair (DDR) pathways modulate cancer risk, progression, and therapeutic
response. We systematically analyzed somatic alterations to provide a comprehensive view …

Most patients with colorectal cancer die as a result of the disease spreading to other organs.
However, no prevalent mutations have been associated with metastatic colorectal cancers …

Numerous large-scale genomic studies of matched tumor-normal samples have established
the somatic landscapes of most cancer types. However, the downstream analysis of data …

Gene expression profiling is nowadays routinely performed on clinically relevant samples
(eg, from tumor specimens). Such measurements are often obtained from bulk samples …

The colorectal adenoma–carcinoma sequence has provided a paradigmatic framework for
understanding the successive somatic genetic changes and consequent clonal expansions …

Over the past several decades, the incidence of early-onset colorectal cancer (EOCRC; in
patients< 50 years old) has increased at an alarming rate. Although robust and scientifically …

Mutations play a fundamental role in the development of cancer, and many create targetable
vulnerabilities. There are both public health and basic science benefits from the …

Colorectal cancers comprise a complex mixture of malignant cells, nontransformed cells,
and microorganisms. Fusobacterium nucleatum is among the most prevalent bacterial …